- Home
- NMRK vs AUPH Comparison
NMRK vs AUPH Comparison
Compare NMRK & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRK | AUPH |
|---|---|---|
| Founded | 1929 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NMRK | AUPH |
|---|---|---|
| Price | $15.40 | $16.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $18.75 | $17.25 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | 100.00 | ★ 5075.00 |
| EPS | 0.08 | ★ 0.25 |
| Revenue | ★ $3,294,024,000.00 | $283,055,000.00 |
| Revenue This Year | $12.45 | $17.54 |
| Revenue Next Year | $8.02 | $15.74 |
| P/E Ratio | $195.63 | ★ $64.88 |
| Revenue Growth | 20.29 | ★ 20.38 |
| 52 Week Low | $12.06 | $8.32 |
| 52 Week High | $19.84 | $19.25 |
Technical Indicators
Market Signals| Indicator | NMRK | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 54.75 | 48.31 |
| Support Level | $15.34 | $14.37 |
| Resistance Level | $15.72 | $19.25 |
| Average True Range (ATR) | 0.47 | 0.91 |
| MACD | 0.07 | -0.16 |
| Stochastic Oscillator | 51.03 | 22.66 |
Price Performance
Historical ComparisonAbout NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.